Over the past 12 months, shares of Amarin have dropped 45% amid uncertainty around Vascepa's NCE status, buyout speculation that never came to fruition, and question marks around the efficacy of fish oil. The company is hoping to get expanded approval for Vascepa and announced today that the FDA's advisory committee meeting date has been set. In the following video, health-care analyst Max Macaluso discusses the importance of this meeting and the risks and opportunities up ahead for this speculative biotech.

Small biotech companies usually crash and burn when it comes to launching drugs -- but can Amarin prove the doubters wrong with its new lipid-lowering drug? In our new premium research report, The Motley Fool's top biotech analyst offers an in-depth look at this drugmaker's upcoming opportunities, along with reasons to buy and sell this stock today. To find out more, simply click here now to claim your copy.

The article Will Amarin's Fish Oil Drug Slip Past the FDA a Second Time? originally appeared on Fool.com.

Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Investing in Startups

The lucrative and risky world of startups.

View Course »

Basics of Diversification

Learn one of the fundamental concepts of building a portfolio.

View Course »

Add a Comment

*0 / 3000 Character Maximum